Sanofi Abandons Oral SERD Breast Cancer Drug As Pipeline Woes Mount

Menarini Remains In Front

 
• By Andrew McConaghie
  
Sanofi
The failure is a blow to Sanofi's hopes of expanding its presence in oncology. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip